RSC Medicinal Chemistry



View Article Online

RESEARCH ARTICLE

Check for updates

Cite this: RSC Med. Chem., 2024, 15, 1746

Received 2nd February 2024, Accepted 10th March 2024

DOI: 10.1039/d4md00086b

rsc.li/medchem

Introduction

Tuberculosis (TB) is a communicable infectious disease caused by *Mycobacterium tuberculosis* (Mtb). Despite global efforts, TB remains one of the world's deadliest killers of the past two decades.^{1–3} In 2023, the World Health Organization (WHO) reported 10.6 million new cases and 1.3 million deaths caused by TB.⁴ In addition, the COVID-19 pandemic is

Design, synthesis and antimycobacterial activity of imidazo[1,5-*a*]quinolines and their zinc-complexes[†]

Michael Marner, ^[10] ^{‡ª} Niclas Kulhanek,^{‡b} Johanna Eichberg,^{ah} Kornelia Hardes,^{ah} Michael Dal Molin,^{ef} Jan Rybniker,^{efg} Michael Kirchner,^b Till F. Schäberle ^{[10] acd} and Richard Göttlich ^{[10] *b}

Tuberculosis has remained one of the world's deadliest infectious diseases. The complexity and numerous adverse effects of current treatment options as well as the emergence of multi-drug resistant *M. tuberculosis* (Mtb) demand research and innovation efforts to yield new anti-mycobacterial agents. In this study, we synthesized a series of imidazo[1,5-*a*]quinolines, including 4 new analogs, and evaluated their activity against Mtb. Inspired by previous studies, we also designed 8 compounds featuring a coordinated metal ion, determined their absolute configuration by single-crystal X-ray diffraction and included them in the bioactivity study. Remarkably, the metal complexation of **5c** with either Zn^{2+} or Fe²⁺ increased the Mtb inhibitory activity of the compound 12.5-fold and reduced its cytotoxicity. Ultimately, out of the 21 analyzed imidazo[1,5-*a*]quinoline analogs, two zinc complexes (**C1** and **C7**) showed the strongest, specific activity against Mtb H37Rv *in vitro* (IC₉₀ = 7.7 and 17.7 μ M).

considered to have erased the progress made in the years up to 2019.^{5,6} The net reduction of the TB incidence from 2015 to 2022 was only 8.7%, missing the important key milestone of the WHO *End TB Strategy* by far (50% reduction until 2025).

Recommended treatment regimens for drug-sensitive Mtb are long and complex (high doses of 4 antibiotics over 4 to 6 months or longer).^{7,8} Non-compliance, *e.g.* misused or mismanaged antibiotic therapy, facilitates the emergence and spread of rifampicin-resistant TB, multidrug-resistant TB and even extensively drug-resistant TB (RR-TB/MDR-TB/XDR-TB). In 2021, the number of MDR-TB cases increased to 450 000. Chemotherapy against MDR-TB and XDR-TB is even



Scheme 1 General synthesis route and isolated yields.

^a Fraunhofer-Institute for Molecular Biology and Applied Ecology (IME) Branch Bioresources, Ohlebergsweg 12, 35392 Giessen, Germany

^b Institute of Organic Chemistry, Justus-Liebig-University, Heinrich-Buff-Ring 17, Giessen 35392, Germany

^c Institute for Insect Biotechnology, Justus-Liebig-University Giessen, Ohlebergsweg 12, 35392, Giessen, Germany

^d German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, Ohlebergsweg 12, 35392 Giessen, Germany

^e Department I of Internal Medicine, University of Cologne, 50937 Cologne, Germany

^f Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany

^g German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany

^h BMBF Junior Research Group in Infection Research "ASCRIBE", Branch for

Bioresources of the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Ohlebergsweg 12, 35392 Giessen, Germany

[†] Electronic supplementary information (ESI) available: General procedures, material and methods. CCDC 2284388, 2284389 and 2284387. For ESI and crystallographic data in CIF or other electronic format see DOI: https://doi.org/ 10.1039/d4md00086b

[‡] The authors contributed equally.



Scheme 2 Employed coupling strategies for the final products.

Table 1 Yields for Negishi coupling

Number	\mathbb{R}^2	R ¹	Isolated product/%
5a ^a	Ph	2-Thiophenyl	58
$5\mathbf{b}^a$	Ph	Ph	84
$5c^a$	Ph	2-Pyridinyl	73
5 d ^{<i>a</i>}	Ph	2-Quinolinyl	79
$5e^b$	Ph	2-Pyrimidinyl	60
$5\mathbf{f}^{b}$	Ph	2-(5-Ph-Pyridinyl)	70
$5g^b$	Ph	3-Isoquinolinyl	79
$5h^a$	Ph	2-Me ₂ N-Ph	40
5i ^a	Ph	2-MeO-Ph	84
6a ^c	2-Pyridyl	2-Pyridinyl	26
6 b ^c	2-Pyridyl	Ph	39
$7a^a$	Nap	2-Pyridinyl	68
8a ^a	NPh_2	2-Pyridinyl	66

Reaction conditions: ^{*a*} Conditions shown in Scheme 2a. ^{*b*} conditions shown in Scheme 2a, products were isolated as hydrochloride salts. ^{*c*} conditions shown in Scheme 2b.

more complicated, and the clinical outcome is generally poor.⁵ Therefore, continuous research and innovation towards new and improved TB active agents is of great importance. A promising approach to improve the potency of

anti-mycobacterial agents is their combination with further antimicrobial molecules.

Transition metals, such as zinc (Zn²⁺), are involved in many physiological processes and are appreciated for their pharmaceutical potential. As part of the innate immune response towards pathogens, macrophages can deploy phagosomal zinc intoxication defence mechanisms.⁹ Antibacterial,¹⁰⁻¹² antifungal¹³ and antiparasitic^{14,15} features of metal-drug complexes have been observed in many studies.

Sonawane *et al.* demonstrated that the activity of rifampicin could be increased by complexing it with Zn^{2+} and encapsulating it into transferrin-conjugated silver quantum dots.¹⁶ In addition, other metal complexes with Cu^{2+} and $V^{5+/4+}$ showed good anti-mycobacterial activity, highlighting the potential use of complexes in TB treatment.^{17,18}

In this early discovery study, we set out to design, synthesize and evaluate the *in vitro* activity of imidazo[1,5-*a*] quinolines. Compounds featuring this core motif have already been reported to exhibit diverse biological activities.^{19–21} However, these scaffolds were never evaluated for their potency towards Mtb. Hence, in the first step, we expanded a set of literature-known imidazo[1,5-*a*]quinolines $(5a-i)^{22}$ with four new structures (6a, 6b, 7a, and 8a) by diversifying substitutions at R¹ and R². The substitution of the imidazole ring was selected based on its synthetic feasibility and reaction yield. Next, we prepared metal complexes of the most intriguing compounds and evaluated their antimycobacterial activity.

Results and discussion

Synthesis and crystal structures

We employed our versatile synthetic route reported in an earlier publication (Scheme 1).²² Here, we introduced R² over an Einhorn acylation and established the imidazo ring system by nucleophilic substitution. **3a–d** was then selectively brominated with *N*-bromosuccinimide at –20 °C.

		$R^{1} \rightarrow N$		
Number	Ligand	Metal salt	Molecular formular	Isolated product/%
21	5c	$ZnCl_2$	[ZnCl ₂ 5c]	95
C2	5c	$FeCl_3$	$[FeCl_2(5c)_2]FeCl_4$	97
3	5c	$Cu(OAc)_2$	$[Cu(OAc)_2 5c]$	98
C 4	7a	$ZnCl_2$	[ZnCl ₂ 7a]	44
25	5e	$ZnCl_2$	[ZnCl ₂ 5e]	40
C 6	5 f	$ZnCl_2$	ZnCl ₂ 5f	64
C 7	5g	$ZnCl_2$	$[ZnCl_25g]$	74
28	8a	$ZnCl_2$	$[ZnCl_28a]$	64

Table 2 General procedure of the complexation reaction and molecular formula of synthesised complexes with yields



Scheme 3 Crystal structures for (a) C1, (b) C2, and (c) C3. Analysed by XRD measurements, solved with ShelXL and visualized with ORTEP-3. Hydrogen atoms are hidden for better visibility (white = carbon, blue = nitrogen, red = oxygen, green = chlorine, cyan = zinc, orange = iron and brown = copper).

Table 3 Minimum inhibitory concentration (MIC) of investigated imidazo[1,5-a]quinolines. Ec: *Escherichia coli* ATCC35218, Sa: *Staphylococcus aureus* ATCC3592; Str: *Septoria tritici* MUCL45408, Mtb: *Mycobacterium tuberculosis* H37Ra; MICs given in μ M. Calu-3: epithelia cell line from lung carcinoma, "—" indicates no effect at 100 μ M and "+" toxic effects at 100 μ M

Number	Ec	Sa	Str	Mtb	Calu-3
5a	>196	>196	>196	>196	_
5b	>200	>200	>200	>200	_
5 c	>199	>199	>199	25	+
5d	>172	>172	>172	86-43	_
5e	>148	>148	>148	1	+
5f	>136	>136	>136	34	_
5g	>144	>144	>144	1 - 0.5	_
5h	>127	>127	>127	2	+
5i	>183	>183	>183	46	_
6a	>198	>198	>198	12-6	_
6b	>199	>199	>199	50-25	+
7a	>172	>172	>172	5-1	+
8a	>155	>155	>155	>155	_
C1	> 140	> 140	>140	2	_
C2	>132	>132	>132	2	_
C3	>127	>127	16-8	2	+
C4	> 126	31.5	63	2-1	+
C5	>140	17-9	17	2-1	+
C6	> 120	>120	>120	8	_
C7	>126	126	126	2-1	_
C8	>117	>117	>117	>117	—

the improved reaction conditions. We observed a high percentage of 3d – an effect that we could not prevent even by longer reaction time or elevated temperature. The ligand character of 3 might have inhibited the activity of the Pd-catalyst. Similarly, the +M-substituent in the R¹ position of 5h might have resulted in a deactivating chelating effect. 5e–5g was converted into their hydrochloride salts to improve their solubility in water (Table 1).

Chelation was performed with the listed ligands (Table 2) in THF. Besides Zn, compound **5c** was also combined with FeCl₃ and Cu(OAc)₂. The structures of **C1** (Scheme 3a), **C2** (Scheme 3b) and **C3** (Scheme 3c) were analysed by XRD from single crystals. The M^{2+} -central atoms showed square planar orientation. **C2** formed an octahedral complex by the displacement of chloride, resulting in a charged complex and, thus, good solvability in water. However, the solubility of the complexes also influenced the isolation yield. The most soluble complexes (**C4–8**) were retrieved in poor yields

Bromides (**4a–c**) were transmetalated with *n*-BuLi and $ZnCl_2$ by Negishi coupling (Scheme 2a). The excess of $ZnCl_2$ in the solution led to the formation of bidentate Zn complexes. The transmetalation with *n*-BuLi resulted in the alkylation of the nitrogen within the pyridine moity of **4d**, forming *n*-butylbromide. We eliminated the presence of halogenoalkanes in the solution using 2 eq. of *t*-BuLi (Scheme 2b).

The majority of products were isolated in good yields of 58-84%. **6a-b** and **5h** were isolated in lower yields even with

Number	Mtb ATCC 35801	HepG2		
	Inhibition at 20 µM	IC_{50}	IC ₉₀	IC_{50}
5g	82%	86.5	136.2	>100
C1	90%	6	7.7	> 100
C2	26%	n.d.	n.d.	n.d.
C7	n.d.	9.1	17.7	83.3

after the washing step. The data evaluation is provided in the supplementary information.

Antimycobacterial activity

The antimicrobial effect of the 21 synthesized compounds was initially accessed against a panel of 4 microbial indicator strains (*Escherichia coli* ATCC35218, *Staphylococcus aureus* ATCC33592, *Septoria tritici* MUCL45408 and *Mycobacterium tuberculosis* H37Ra). Cytotoxicity was investigated using an epithelia cell line from human lung carcinoma (Calu-3). The results are summarized in Tables 3 and S1.[†]

From the investigated compounds, 13 showed no cytotoxicity at a high dose of 100 μ M. Simultaneously, 4 (5g, C1, C2, C7) of the non-toxic compounds exhibited an intriguing MIC of $\leq 2 \mu$ M against our surrogate Mtb strain H37Ra. These values are in range or only slightly higher than MICs of the reference drugs used in this study (MIC of gentamicin against H37Ra = 4 μ M and MIC of rifampicin 0.07 μ M; see Table S1 in ESI†) and literature reported values against various Mtb strains (*e.g.* isoniazid = 0.3–1.4 μ M; levofloxacin = 0.8–1.4 μ M, amikacin = 0.4–1.7 μ M, bendaquiline = 0.03–1 μ M, ethambutol = 0.3–3 μ M or ethionamide = 10 μ M).^{23–26}

Interestingly, the low antimycobacterial activity of **5c** against H37Ra (25 μ M) could be potentiated by a factor of 12.5 by complexation with either Zn²⁺ (C1), Fe3⁺ (C2) or Cu2⁺ (C3). Although the copper-acetate complex maintained the initially observed cytotoxic properties of **5c**, we observed no toxicity of the Zn²⁺ and Fe³⁺ complexes towards the Calu-3 lung carcinoma cell line at 100 μ M.

The inhibitory effects of **5g**, **C1**, **C2**, and **C7** were specifically observed against Mtb, while the other test strains were not affected. These 4 compounds were then screened in a second-tier assay against wild-type *Mycobacterium tuberculosis* strain ATCC 35801. After activity confirmation at a high dose of 20 μ M, the MIC values were determined. Cytotoxicity was also revaluated in the human liver cancer cell line HepG2 (Table 4, Fig. S1–S6†).

Although the promising activity of C1 against H37Ra could be transferred to the wild-type strain ATCC 35801 (IC_{50/90} = 6/ 7.7 μ M), C2 showed no growth inhibitory effects against this strain. Similarly, the initially promising growth inhibitory activity of 5g against the Mtb surrogate (1 μ M) could not be transferred to the virulent Mtb strain (IC_{50/90} = 86.5/132.2 μ M), but the potency was strongly increased (IC_{50/90} = 9.14/ 17.72 μ M) upon Zn²⁺ complexation (C7). The other designed imidazo[1,5-*a*]quinoline-Zn²⁺ complexes were either cytotoxic (C4–C5) or inactive (C6, C8).

Conclusions

In summary, we synthesized a series of 21 imidazo[1,5-*a*] quinolines and screened them against the surrogate strain *M. tuberculosis* HR37a, as well as against *Escherichia coli, Staphylococcus aureus,* the fungal plant pathogen *Septoria tritici* and lung carcinoma cell line Calu-3. Inspired by

previous reports, we also decided to include metal-chelated variants in the compound series. To the best of our knowledge, the present study is the first to describe the antimycobacterial effects of imidazo[1,5-*a*]quinolines. Interestingly, the initially moderate antimycobacterial activity of **5c** against H37Ra (25 μ M) could be potentiated by a factor of 12.5 by complexation with either Zn²⁺ or Fe²⁺, while the cytotoxic effect was reduced (>100 μ M).

Besides compounds C1 and C2, two additional compounds (5g and C7) exhibited specific HR37a activity (<2 µM) and were therefore followed up in a second-tier assay against BSL-3 Mycobacterium tuberculosis ATCC 35801. Ultimately, we identified two zinc complexes C1 and C7, with intriguing anti-tuberculosis activity and low cytotoxicity. Although these compounds surfaced from a relatively small derivative library, their in vitro potency was comparable to that of developed Mtb drugs. However, the major challenge regarding TB is the treatment of multi-drug resistant forms of the disease for which currently available drugs are not effective.²⁷ Hence, it would be of interest to profile our candidates against RR-TB, MDR-TB and XDR-TB strains. Additional work investigating the mode of action, frequency of resistance, cross resistance, collateral susceptibility effects as well as ADME Tox properties of target compounds is crucial to evaluate their clinical potential.

Author contributions

M. Marner performed the biological studies and prepared the draft. N. Kulhanek performed the synthesis and analytics and prepared the draft. N. Kulhanek and M. Marner contributed equally to this publication. Johanna Eichberg performed cytotoxicity analysis and Michael Dal Molin conducted BSL-3 work. M. Kirchner analysed and solved the XRD data.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors would like to thank K. S. Bommersheim for her technical support during the MIC determinations. The work in the Schäberle lab was supported by the State Ministry of Higher Education, Research and Arts of the state Hessen through the LOEWE program for the Center for Insect Biotechnology and Bioresources and by the German Center for Infection Research. The work in the Junior Research Group in Infection Research "ASCRIBE" of K. Hardes was supported by the Federal Ministry of Education and Research (BMBF).

References

 T. M. Daniel, J. H. Bates and K. A. Downes, in *Tuberculosis*, ed. B. R. Bloom, ASM Press, Washington, D. C, 1994, pp. 13–24.

Research Article

- 2 I. Barberis, N. L. Bragazzi, L. Galluzzo and M. Martini, J. Prev. Med. Hyg., 2017, 58, E9–E12.
- 3 T. Paulson, Nature, 2013, 502, S2-S3.
- 4 World Health Organization, *Global Tuberculosis Report 2023*, WHO, Geneva, 2023, https://www.who.int/teams/globaltuberculosis-programme/tb-reports/global-tuberculosisreport-2023, (accessed 19 February 2024).
- 5 World Health Organization, *Global Tuberculosis Report 2022*, WHO, Geneva, 2022, https://www.who.int/teams/globaltuberculosis-programme/tb-reports/global-tuberculosisreport-2022, (accessed 9 October 2023).
- 6 C. F. McQuaid, A. Vassall, T. Cohen, K. Fiekert and R. G. White, *Int. J. Tuberc. Lung. Dis.*, 2021, **25**, 436–446.
- 7 Centers for Disease Control and Prevention (CDC), *Treatment for TB Disease*, USA, 2023, https://www.cdc.gov/tb/topic/treatment/tbdisease.htm, (accessed 9 October 2023).
- 8 National Health Service (NHS), Clinical Commissioning Policy Statement: Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid, England, 2019, https://www.england.nhs.uk/commissioning/wp-content/ uploads/sites/12/2019/07/clinical-commissioning-policystatement-treatment-for-defined-patients-with-mdr-tb-andxdr-updated-dec-20.pdf, (accessed 9 October 2023).
- 9 C. J. Stocks, J. B. von Pein, J. E. B. Curson, J. Rae, M.-D. Phan, D. Foo, N. J. Bokil, T. Kambe, K. M. Peters, R. G. Parton, M. A. Schembri, R. Kapetanovic and M. J. Sweet, *J. Leukocyte Biol.*, 2021, **109**, 287–297.
- 10 S. Hayet, M. Ghrayeb, D. N. Azulay, Z. Shpilt, E. Y. Tshuva and L. Chai, *RSC Med. Chem.*, 2023, 14, 983–991.
- 11 T. Damena, D. Zeleke, T. Desalegn, T. B. Demissie and R. Eswaramoorthy, *ACS Omega*, 2022, 7, 4389–4404.
- B. Duffy, C. Schwietert, A. France, N. Mann, K. Culbertson,
 B. Harmon and J. P. McCue, *Biol. Trace Elem. Res.*, 1998, 64, 197–213.
- 13 Z. H. Chohan, H. Pervez, A. Rauf, K. M. Khan and C. T. Supuran, *J. Enzyme Inhib. Med. Chem.*, 2004, **19**, 417–423.
- J. A. de Azevedo-França, R. Granado, S. T. de Macedo Silva, G. D. Santos-Silva, S. Scapin, L. P. Borba-Santos, S. Rozental, W. de Souza, É. S. Martins-Duarte, E. Barrias, J. C. F. Rodrigues and M. Navarro, *Antimicrob. Agents Chemother.*, 2020, 64(5), DOI: 10.1128/aac.01980-19.

- 15 T. J. Hubin, P. N.-A. Amoyaw, K. D. Roewe, N. C. Simpson, R. D. Maples, T. N. Carder Freeman, A. N. Cain, J. G. Le, S. J. Archibald, S. I. Khan, B. L. Tekwani and M. O. F. Khan, *Bioorg. Med. Chem.*, 2014, 22, 3239–3244.
- 16 R. Pati, R. Sahu, J. Panda and A. Sonawane, *Sci. Rep.*, 2016, **6**, 24184.
- 17 D. A. Paixão, I. M. Marzano, E. H. L. Jaimes, M. Pivatto, D. L. Campos, F. R. Pavan, V. M. Deflon, P. I. S. Da Maia, A. M. Da Costa Ferreira, I. A. Uehara, M. J. B. Silva, F. V. Botelho, E. C. Pereira-Maia, S. Guilardi and W. Guerra, *J. Inorg. Biochem.*, 2017, **172**, 138–146.
- 18 I. Correia, P. Adão, S. Roy, M. Wahba, C. Matos, M. R. Maurya, F. Marques, F. R. Pavan, C. Q. F. Leite, F. Avecilla and J. Costa Pessoa, *J. Inorg. Biochem.*, 2014, **141**, 83–93.
- 19 A. Cappelli, M. Anzini, F. Castriconi, G. Grisci, M. Paolino, C. Braile, S. Valenti, G. Giuliani, S. Vomero, A. Di Capua, L. Betti, G. Giannaccini, A. Lucacchini, C. Ghelardini, L. Di Cesare Mannelli, M. Frosini, L. Ricci, G. Giorgi, M. P. Mascia and G. Biggio, *J. Med. Chem.*, 2016, **59**, 3353–3372.
- 20 D. C. Mungra, M. P. Patel and R. G. Patel, *Med. Chem. Res.*, 2011, 20, 782–789.
- 21 V. Srinivasulu, M. Khanfar, H. A. Omar, R. ElAwady, S. M. Sieburth, A. Sebastian, D. M. Zaher, F. Al-Marzooq, F. Hersi and T. H. Al-Tel, *J. Org. Chem.*, 2019, 84, 14476–14486.
- 22 N. Kulhanek, N. Martin and R. Göttlich, *Eur. J. Org. Chem.*, 2024, 27(1), DOI: 10.1002/ejoc.202301007.
- 23 K. Kaniga, D. M. Cirillo, S. Hoffner, N. A. Ismail, D. Kaur, N. Lounis, B. Metchock, G. E. Pfyffer and A. Venter, *J. Clin. Microbiol.*, 2016, 54, 2956–2962.
- 24 M. T. Heinrichs, R. J. May, F. Heider, T. Reimers, S. K. B. Sy, C. A. Peloquin and H. Derendorf, *Int. J. Mycobact.*, 2018, 7, 156–161.
- 25 N. J. E. Waller, C.-Y. Cheung, G. M. Cook and M. B. McNeil, *Nat. Commun.*, 2023, 14, 1517.
- 26 T. Schön, J. Werngren, D. Machado, E. Borroni, M. Wijkander, G. Lina, J. Mouton, E. Matuschek, G. Kahlmeter, C. Giske, M. Santin, D. M. Cirillo, M. Viveiros and E. Cambau, *Clin. Microbiol. Infect.*, 2020, **26**, 1488–1492.
- 27 I. Barilar, T. Fernando, C. Utpatel, C. Abujate, C. M. Madeira, B. José, C. Mutaquiha, K. Kranzer, T. Niemann, N. Ismael, L. de Araujo, T. Wirth, S. Niemann and S. Viegas, *Lancet Infect. Dis.*, 2024, 24, 297–307.